Pharmaceuticals News

DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery...

PARAMUS, NJ, April 01, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric...

MISSISSAUGA, Ontario, 01 avr. 2026 (GLOBE NEWSWIRE) -- BioSyent inc. (« BioSyent », Bourse de croissance TSX : RX) est heureuse d’annoncer que FeraMAXMD a été désigné supplément de fer en vente...

WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet...

Axe Compute signs $12M in enterprise GPU agreements, entering Q2 2026 with $835K in estimated monthly income across 20+ customers.

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...

Bezuclastinib NDA submitted under the FDA’s RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib...

ROCKAWAY, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the publication of new clinical...

- Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical measures of functional improvement for managed care...

Achieved positive adjusted EBITDA in Q4 2025 and near break-even $(0.29) million for the full year Advancements across business units, R&D, and clinical development to support scale and...